Director, Lymphoma Program
Medical Director, Oncology Data Center
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York
Associate Scientific Director
Senior Scientific Director
Associate Director, Scientific Services
Senior Director, Educational Strategy
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff and reviewers of Clinical Care Options, LLC and Purdue University College of Pharmacy have no relationships to disclose.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximumof 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This program has been approved for 1.0 contact hour
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-045-H01-P, 1.0 contact hours (0.1 CEU).
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2019, through July 08, 2020:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Commentary on pharmacist’s role in preventing, identifying, and caring for patients experiencing CAR T-cell–associated acute and long-term toxicities.
CME-certified interactive virtual presentation from Clinical Care Options (CCO) with case-based expert insights on using targeted therapies for treating patients with CLL
Downloadable slides on the most recent clinical data on targeted therapies in CLL from Clinical Care Options (CCO).
Download these slides to review the latest clinical data informing optimal management of β-thalassemia, including for new and emerging novel therapies.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.